Driving Innovation in Radiopharmaceutical Therapies

Oncology clinical research is complex, demanding, and continually evolving. Bringing effective radiopharmaceutical therapies from proof-of-concept and then to market as fast as possible is our focus because every second counts for patients with cancer and their families.

The promise of radiopharmaceutical research

The need for new, innovative therapies for cancer has never been greater. There were an estimated 20 million new cancer cases and 9.7 million deaths in 2022, and the incidence of cancer is expected to continue rising.

Radiopharmaceuticals are a relatively new, evolving class of cancer therapy proving highly effective at diagnosing and treating cancer. In contrast to traditional radiation therapy, which uses external beams or brachytherapy that often affects both cancerous and healthy tissue, radiopharmaceuticals target and kill cancer cells by delivering precise, DNA-damaging radiation therapy directly to tumors.

Trends and advancements in radiopharmaceutical research

• Highly targeted radioisotopes minimizing damage to adjacent healthy tissue
• New applications, such as radioligand therapy (RLT), in treatment-resistant cancers, including lung, prostate, brain, and gastrointestinal
• Effective combination therapies with targeted and immunotherapies
• Complex development; large pharma investing
  ‐ Partnering/acquiring biotechs with radiopharmaceutical pipelines
  ‐ Building/enhancing manufacturing capacity
  ‐ Optimizing regulatory pathway
• Advancement of theranostics in cancer therapy
  ‐ Using radioactive substance to locate (diagnose) and then treat a tumor with a targeted therapy

Challenges in radiopharmaceutical research

• Radiopharmaceutical supply chain challenges
  ‐ Supplies limited
  ‐ Complex shipping, handling, storage, and disposal requirements
• Radioisotopes with short half-life require rapid, just-in-time patient dosing impacting logistics of patient enrollment
• Necessary early-stage dosimetry, resulting in increased study timelines and patient involvement prior to therapy
• Facility licensing needed for production, shipping, and receiving radioisotopes
• Regulatory requirements by country may differ widely
• Need for highly-trained nuclear medicine department sites close to manufacturing sites

91% Corporate retention rate

• A transparent people-first culture with industry-leading retention
• We are responsive and attentive to the needs of both our customers and staff. Our industry-leading employee and project team retention guarantee program continuity, increased efficiency, and happy investigative sites

Exclusively biotech-focused

Built to work exclusively with biotechs, our flexible processes and approach allow us to listen first, align goals, and execute with an eye toward rapid shifts when protocols amend or Breakthrough designations move a product straight from Phase I to registration.

Seasoned oncology experts  

With an average of 9+ years of oncology experience for key roles (PM, CTL, DM, Clinical Science), our oncology specialty guarantees you a seasoned team across all functions.

Additional differentiators 

Active next-gen oncology experience

Working both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.